Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Subsidiary Pays $9.75M To Resolve Kickback Allegations

Executive Summary

DePuy Synthes reportedly provided a Massachusetts surgeon with more than $100,000 in free implants and tools.

You may also be interested in...



Warning Letters And Close-Outs – September 2023

It was a quiet month for warning letters at the FDA last month, with the agency issuing no new warning letters and closing out only one. 

Proposed Rule Would Apply FDA’s Diagnostic Rules To LDTs

A proposed rule from the US Food and Drug Administration would allow the agency to take on regulation of lab-developed tests by phasing out the previous approach of enforcement discretion

OMB Clears Proposed Rule On Lab-Developed Tests

The US FDA appears poised to release long-promised regulations on lab-developed tests. However, some industry observers still have doubts as to whether the agency is truly prepared. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel